Attributes | Values |
---|
rdf:type
| |
Description
| - Absorption rates of the phosphate-buffered insulin analogs aspart, lispro, and glulisine prevail over that of regular human insulin. The aim of this prospective observational open-label controlled study was to compare the effects of aspart and human regular insulin resulting from their sequential long-lasting routine administration in small preprandial boluses to individuals with type 2 diabetes acccording to identical algorithms
- Absorption rates of the phosphate-buffered insulin analogs aspart, lispro, and glulisine prevail over that of regular human insulin. The aim of this prospective observational open-label controlled study was to compare the effects of aspart and human regular insulin resulting from their sequential long-lasting routine administration in small preprandial boluses to individuals with type 2 diabetes acccording to identical algorithms (en)
- Cíl: Cílem této prospektivní observační otevřené studie bylo porovnat účinky inzulínem Aspart s účinky krátkodobého humánního inzulínu při dlouhodobém podávání v malých prepondiálních dávkách osobám s diabetem 2. typu na základě stejných algoritmů. Metoda: Bylo vyšetřeno 57 osob s DM 2. typu (cs)
|
Title
| - Benefits of complementary therapy with insulin aspart versus human regular insulin in persons with type 2 diabetes mellitus
- Benefits of complementary therapy with insulin aspart versus human regular insulin in persons with type 2 diabetes mellitus (en)
- Výhody komplementární léčby inzulin aspartátem versus normálním lidským inzulinem u nemocných s diabetem II. typu (cs)
|
skos:prefLabel
| - Benefits of complementary therapy with insulin aspart versus human regular insulin in persons with type 2 diabetes mellitus
- Benefits of complementary therapy with insulin aspart versus human regular insulin in persons with type 2 diabetes mellitus (en)
- Výhody komplementární léčby inzulin aspartátem versus normálním lidským inzulinem u nemocných s diabetem II. typu (cs)
|
skos:notation
| - RIV/00216208:11120/07:00001307!RIV09-MZ0-11120___
|
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| - P(NR7825), Z(MZ00000064211)
|
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/00216208:11120/07:00001307
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - insulin Aspart; complementary insulin therapy; type 2 diabetes mellitus (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| - US - Spojené státy americké
|
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| - Diabetes Technology & Therapeutics
|
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...vavai/riv/projekt
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| - Zatloukal, Petr
- Zapletalová, J.
- Doubravová, B.
- Chlupová, L.
- Malá, E.
- Pukowietz, L.
- Chlup, R.
- Seckar, P.
- Tancošová, S.
|
http://linked.open...ain/vavai/riv/wos
| |
http://linked.open...n/vavai/riv/zamer
| |
issn
| |
number of pages
| |
http://localhost/t...ganizacniJednotka
| |
is http://linked.open...avai/riv/vysledek
of | |